177Lu-DOTA-EB-FAPI
/ Xiamen University
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
April 01, 2025
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: The First Affiliated Hospital of Xiamen University | Recruiting ➔ Completed | N=20 ➔ 12
Enrollment change • Trial completion • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma
October 18, 2024
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients with Various Solid Tumors
(clinicaltrials.gov)
- P2 | N=28 | Completed | Sponsor: The First Affiliated Hospital of Xiamen University | Recruiting ➔ Completed | Phase classification: P1 ➔ P2 | N=20 ➔ 28 | Trial completion date: Jun 2025 ➔ Oct 2024 | Trial primary completion date: Dec 2024 ➔ Sep 2024
Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
July 27, 2023
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University
New P1 trial • Oncology • Solid Tumor • FAP
June 27, 2023
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University | Phase classification: P2 ➔ P1
Metastases • Phase classification • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • FAP
August 04, 2022
Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer
(clinicaltrials.gov)
- P2 | N=20 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University | Not yet recruiting ➔ Recruiting
Enrollment open • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • FAP
June 08, 2022
Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer
(clinicaltrials.gov)
- P2 | N=20 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University
New P2 trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma
1 to 6
Of
6
Go to page
1